A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole

Journal of Infection

Volumn 51, Issue 3, 2005, Pages

  Clark, Ben ^a   Foster, R ^a   Tunbridge, A ^a   Green, S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Disseminated histoplasmosis; Posaconazole

Indexed keywords

DIGOXIN; FUROSEMIDE; ITRACONAZOLE; POSACONAZOLE; WARFARIN;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; ELECTROLYTE DISTURBANCE; FEVER; HEART ATRIUM FIBRILLATION; HISTOPLASMOSIS; HUMAN; LABORATORY DIAGNOSIS; MALE; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; WEIGHT REDUCTION;

AGED; ANTIFUNGAL AGENTS; DRUGS, INVESTIGATIONAL; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; MALE; TREATMENT OUTCOME; TRIAZOLES;

EID: 27644563878     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2005.01.001     Document Type: Article

References (19)

1. L.J. Wheat C.A. Kauffman Histoplasmosis Infect Dis Clin North Am 17 2003 1-19
2. J. Wheat G. Sarosi D. McKinsey et al. Practice guidelines for the management of patients with histoplasmosis: Infectious Diseases Society of America Clin Infect Dis 30 2000 688-695
3. G.S. Deepe Jr Histoplasma capsulatum In: G.L. Mandall J.E. Bennett R. Dolin editors. Principles and practice of infectious diseases 5th ed 2000 Churchill Livingstone Philadelphia, PA 2718-2733
4. C. Farina F. Gnecchi G. Michetti A. Parma C. Cavanna P. Nasta Imported and autochthonous histoplasmosis in Bergamo province, Northern Italy Scand J Infect Dis 32 2000 271-274
5. L. Calza R. Manfredi C. Donelli G. Marinacci V. Colangeli F. Chiodo Disseminated histoplasmosis with atypical cutaneous lesions in an Italian HIV-infected patient: Another autochtomous case HIV Med 4 2003 145-148
6. J. Gascon J.M. Torres P. Luburich J.R. Ayuso A. Xuabet M. Corachan Imported histoplasmosis in Spain J Travel Med 7 2000 89-91
7. A.A. Panackal R.A. Hajjeh M.S. Cetron D.W. Warnock Fungal infections among returning travellers Clin Infect Dis 35 2002 1088-1095
8. M.V. Cano R.A. Hajjeh The epidemiology of histoplasmosis: A review Semin Respir Infect 16 2001 109-118
9. P.C. Johnson G.A. Sarosi Histoplasmosis Semin Respir Med 9 1987 145-151
10. A.D. Luber L. Maa M. Lam B.J. Guglielmo Risk factors for amphotericin B-induced nephrotoxicity J Antimicrob Chemother 43 1999 267-271
11. S. Harbarth S.L. Pestotnik J.F. Lloyd J.P. Burke M.H. Samore The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy Am J Med 111 2002 528-534
12. A. Espinel-Ingroff Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts J Clin Microbiol 36 1998 2950-2956
13. P. Connolly J. Wheat C. Schnizlein-Bick et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice Antimicrob Agents Chemother 43 1999 322-328
14. P. Connolly L.J. Wheat C. Schnizlein-Bick et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice Antimicrob Agents Chemother 44 2000 2604-2608
15. L.J. Wheat Current diagnosis of histoplasmosis Trends Microbiol 11 2003 488-494
16. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:198-92.
17. P. Krieter B. Flannery T. Musick M. Gohdes M. Martinho R. Courtney Disposition of posaconazole following single-dose oral administration in healthy subjects Antimicrob Agents Chemother 48 2004 3543-3551
18. Greenberg RN. Posaconazole therapy for refractory invasive zygomycosis. Poster presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract M-1757. Chicago, IL; September 14-17, 2003.
19. Ullmann AJ, Cornely OA, Burchardt A, et al. Safety and efficacy of posaconazole (POS) in a pharmacokinetic study in patients with febrile neutropenia (FN) or refractory invasive fungal infections (rIFI). Poster presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract M-1257. Chicago, IL; September 14-17, 2003.